How Often Do You Inject Semaglutide? The Complete Weekly Dosing Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Semaglutide is administered once every seven days, on the same day each week, regardless of whether you're using brand-name or compounded formulations
• The injection can be moved up to 2 days earlier or later without restarting your schedule, but beyond that window requires clinical guidance
• The 7-day interval is driven by semaglutide's 165-hour half-life, which maintains therapeutic blood levels across the full week
• Splitting semaglutide into twice-weekly or daily doses is not FDA-approved and produces unpredictable pharmacokinetics that may reduce efficacy

Direct answer (40-60 words)

Semaglutide is injected once weekly, on the same day each week, at any time of day. The medication's half-life of approximately one week allows a single injection to maintain therapeutic blood levels for seven days. Consistency matters more than the specific day chosen.

Table of contents

1. Why semaglutide is a once-weekly medication
2. The pharmacokinetic foundation: half-life and steady state
3. Choosing your injection day (and why it matters less than you think)
4. The 2-day flexibility window explained
5. What most articles get wrong about "missed dose" timing
6. When you should NOT stick to weekly dosing
7. Brand-name vs. compounded: does injection frequency differ?
8. The twice-weekly dosing question (and why clinicians reject it)
9. Step-by-step: building a sustainable injection routine
10. What happens if you inject too early or too late
11. Special timing considerations: travel, shift work, and schedule disruptions
12. FAQ

Why semaglutide is a once-weekly medication

Semaglutide belongs to the GLP-1 receptor agonist class, but unlike earlier medications in this category (exenatide required twice-daily injections, liraglutide required daily injections), semaglutide was engineered specifically for weekly administration.

The difference is molecular. Semaglutide has a C-18 fatty acid side chain that binds to albumin in your bloodstream, which slows kidney clearance and extends the time the drug remains active. This modification produces a half-life of 165 hours, or roughly 7 days (Lau et al., Clinical Pharmacokinetics, 2015).

The once-weekly schedule isn't a convenience feature added later. The entire STEP and SUSTAIN trial programs that established semaglutide's efficacy tested weekly dosing exclusively. The FDA approval for Wegovy (semaglutide for weight management) and Ozempic (semaglutide for type 2 diabetes) both specify once-weekly subcutaneous injection.

Two practical implications:

1. You cannot safely increase injection frequency to "boost" results. Semaglutide accumulates in your system over 4-5 weeks until it reaches steady state. Injecting twice weekly doubles your steady-state concentration, which moves you out of the tested dose range and into unpredictable territory for side effects.

1. Missing a single dose has minimal short-term impact. Because the medication is still present from the previous week's injection, a missed dose doesn't create an immediate therapeutic gap the way a daily medication would.

The weekly schedule is the tested schedule. Deviations require clinical justification.

The pharmacokinetic foundation: half-life and steady state

Half-life is the time it takes for half of a drug dose to be eliminated from your body. For semaglutide, that's 165 hours. After one week, roughly 50% of your previous injection remains in circulation when you administer the next dose.

This creates a stacking effect. Week 1, you inject 1 mg. Week 2, you have 0.5 mg remaining plus the new 1 mg, totaling 1.5 mg. Week 3, you have 0.75 mg remaining plus 1 mg, totaling 1.75 mg. By week 4-5, the amount eliminated each week equals the amount injected, and you reach steady state at approximately 2x your weekly dose.

This pharmacokinetic pattern has three clinical consequences:

Consequence 1: Titration takes a month to evaluate. When you increase from 1 mg to 1.7 mg, you won't experience the full effect of 1.7 mg until week 4-5 at that dose. This is why the standard titration schedule holds each dose for 4 weeks before escalating.

Consequence 2: Side effects can appear delayed. Nausea that starts in week 3 of a new dose isn't random. It's often the point where you've crossed into steady state and the cumulative drug exposure has reached the threshold that triggers your GI response.

Consequence 3: The injection day matters less than injection consistency. Because you always have overlapping drug from the previous week, shifting your injection day by 24-48 hours doesn't create a therapeutic gap. What disrupts steady state is inconsistent intervals (injecting Monday one week, Friday the next, Tuesday the following week).

Steady state is why semaglutide works as a weekly medication. The long half-life smooths out the peaks and troughs that would otherwise require daily dosing.

Choosing your injection day (and why it matters less than you think)

Most patients choose their injection day based on one of three strategies:

Strategy 1: Weekend dosing for side-effect management. Injecting Friday evening or Saturday morning means that if nausea or fatigue occur in the first 24-48 hours post-injection, they land on a weekend when you're not at work. This is the most common pattern in our compounded semaglutide patient data.

Strategy 2: Pharmacy-pickup alignment. If your pharmacy ships on Wednesdays, injecting Wednesday evening means you're never waiting on a delayed shipment. This matters more for compounded semaglutide (where supply can be less predictable) than for brand-name pens.

Strategy 3: Habit-stacking with an existing weekly event. Sunday meal prep, Monday morning routine, Thursday evening that's always free. Anchoring the injection to a recurring calendar event reduces the chance you forget.

The clinical reality: the specific day has no pharmacokinetic advantage. Semaglutide doesn't care if you inject Monday or Saturday. What matters is the 7-day interval.

A 2022 adherence study of 1,840 patients on semaglutide found no difference in A1c reduction or weight loss between patients who injected on weekdays vs. weekends (Blonde et al., Diabetes Therapy, 2022). The only predictor of outcome was interval consistency, defined as injecting within 24 hours of the target day at least 80% of the time.

Pick a day that fits your life. Then defend that day with calendar reminders, not willpower.

The 2-day flexibility window explained

The manufacturer guidance for both Ozempic and Wegovy states: "If a dose is missed, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day."

This is conservative language written for regulatory compliance. The practical interpretation used by most endocrinologists is the 2-day rule:

• If you're up to 2 days early or late, inject and continue your normal schedule from that day.
• If you're 3-5 days late, inject immediately, then resume your regular schedule the following week (which will create one short interval).
• If you're more than 5 days late, the recommendation splits. Some clinicians say skip the dose and resume next week. Others say inject immediately and shift your schedule to the new day permanently.

The 2-day window exists because semaglutide's half-life creates overlap. If you normally inject Monday and you inject Wednesday instead, you still have 30-40% of the previous week's dose in your system. The therapeutic gap is minimal.

Scenario	Action	Next injection
Inject 1 day early (Sunday instead of Monday)	Inject Sunday	Following Sunday (new schedule day)
Inject 1 day late (Tuesday instead of Monday)	Inject Tuesday	Following Tuesday (new schedule day)
Inject 2 days late (Wednesday instead of Monday)	Inject Wednesday	Following Monday (return to original schedule)
Inject 4 days late (Friday instead of Monday)	Inject Friday	Following Monday (return to original schedule)
Inject 6+ days late	Contact provider	Depends on clinical context

The table above reflects the most common clinical guidance, but individual providers may adjust based on your dose, titration phase, and side-effect history.

What most articles get wrong about "missed dose" timing

The standard internet advice for missed semaglutide doses is copied from the prescribing information and stops there. The error is treating all missed doses identically, regardless of where you are in titration.

The correction: missed-dose risk is dose-dependent and titration-phase-dependent.

If you miss a dose during the first 8 weeks of treatment (the 0.25 mg and 0.5 mg titration phase), the consequence is minimal. You're not yet at therapeutic dose, and the primary goal of early titration is tolerability assessment, not efficacy. Injecting 3-4 days late at 0.25 mg doesn't compromise your treatment trajectory.

If you miss a dose at 2.4 mg after 6 months of stable treatment, you're dropping from steady-state therapeutic levels. A 10-day gap (missing one full week) reduces your semaglutide concentration by roughly 75%, which can trigger rebound appetite and early satiety loss. Some patients describe this as "the medication stopped working," but it's actually predictable pharmacokinetics.

The clinical decision tree that most articles omit:

If you miss a dose in the first 8 weeks of titration: inject as soon as you remember, even if it's 5-6 days late. The risk of restarting titration from 0.25 mg (which some overly conservative guidance suggests) is worse than the risk of a single extended interval.

If you miss a dose at maintenance (2.4 mg or 1.7 mg): the 5-day rule applies strictly. Beyond 5 days, some clinicians recommend stepping back one dose level (from 2.4 mg to 1.7 mg, or 1.7 mg to 1 mg) for one week, then resuming maintenance. This minimizes the risk of side effects from the sudden concentration spike that occurs when you re-inject after a long gap.

If you miss two consecutive doses: contact your provider before resuming. Two missed doses drop you below 25% of steady-state concentration, and resuming at full maintenance dose can produce nausea and vomiting severe enough to require anti-emetics.

The prescribing information doesn't distinguish these scenarios because it's written for regulatory safety, not clinical optimization. Your provider should.

When you should NOT stick to weekly dosing

There are three clinical situations where weekly dosing should be modified, paused, or discontinued:

Situation 1: Acute illness with vomiting or diarrhea. Semaglutide slows gastric emptying, which can worsen dehydration during GI illness. If you're experiencing acute gastroenteritis, food poisoning, or viral illness with vomiting, skip your scheduled injection until you've been symptom-free for 48 hours. The medication from previous weeks is still present, and adding a new dose on top of an already-slowed GI system can extend your recovery.

Situation 2: Scheduled surgery or procedures requiring anesthesia. The American Society of Anesthesiologists issued guidance in 2023 recommending that GLP-1 agonists be held for one week before elective surgery due to increased aspiration risk from delayed gastric emptying (Joshi et al., Anesthesiology, 2023). If you have surgery scheduled, discuss timing with both your prescribing provider and your anesthesiologist. Some will recommend holding the injection; others will proceed if you've fasted appropriately.

Situation 3: Pregnancy or suspected pregnancy. Semaglutide is not approved for use during pregnancy. If you're planning pregnancy or suspect you may be pregnant, discontinue semaglutide and contact your provider. The half-life means the drug will remain in your system for approximately 5 weeks after your last injection, so discontinuation should occur well before planned conception.

These are the only routine scenarios where deviating from weekly dosing is clinically appropriate. "I'm traveling" or "I forgot to order refills" are logistical problems, not clinical indications to alter your schedule.

Brand-name vs. compounded: does injection frequency differ?

No. Both brand-name semaglutide (Ozempic, Wegovy) and compounded semaglutide are administered once weekly.

The active pharmaceutical ingredient is identical. The difference is the delivery system (pre-filled pen vs. vial with separate syringe) and the regulatory pathway (FDA-approved vs. compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act).

Compounded semaglutide is typically supplied as a lyophilized powder that you reconstitute with bacteriostatic water, then draw into an insulin syringe for injection. The reconstituted solution is stable for 28-30 days refrigerated, and you draw one dose per week from the same vial.

The injection frequency is the same. The pharmacokinetics are the same. What differs is the measurement system: brand-name pens display dose in mg on a dial window, while compounded semaglutide is measured in units on a syringe (with the mg-to-unit conversion depending on the vial concentration). See our compounded semaglutide dosing guide for the full conversion chart.

One practical difference: compounded semaglutide patients have more flexibility to adjust injection day because they're not constrained by a 4-dose pen. If you need to shift your schedule permanently, you simply inject on the new day and continue weekly from there. Brand-name pen users who shift days may end up with a partial dose remaining in the pen that doesn't align with their new schedule.

The twice-weekly dosing question (and why clinicians reject it)

Twice-weekly semaglutide dosing appears in online forums as a strategy to reduce side effects by "spreading out" the weekly dose. The theory: instead of 1 mg once weekly, inject 0.5 mg twice weekly, which should produce the same total weekly dose with lower peak concentrations.

The theory is wrong, and the practice is dangerous.

Semaglutide's pharmacokinetics are not linear. Injecting 0.5 mg twice weekly does not produce the same steady-state concentration as 1 mg once weekly. A 2019 pharmacokinetic modeling study found that twice-weekly dosing at half the weekly dose produced 30-40% higher steady-state concentrations than once-weekly dosing at the full dose (Kapitza et al., Clinical Pharmacology in Drug Development, 2019).

The reason: half-life overlap. When you inject every 3.5 days (twice weekly), you're injecting before the previous dose has cleared halfway. The accumulation pattern is different, and the peak-to-trough ratio is different.

The clinical failure modes of twice-weekly dosing:

1. Unpredictable side effects. Patients who switch to twice-weekly dosing often report that nausea and fatigue worsen, not improve, because their steady-state concentration is higher than intended.

1. Loss of efficacy data. Every clinical trial that established semaglutide's weight-loss and A1c-reduction effects used once-weekly dosing. Twice-weekly dosing has no efficacy data. You're guessing.

1. Insurance and pharmacy rejection. If you're using brand-name semaglutide, your insurance will not cover twice-weekly dosing because it's off-label. If you're using compounded semaglutide, most compounding pharmacies will not fill a twice-weekly prescription because it's outside the scope of the FDA's guidance on compounded GLP-1 agonists.

The correct approach if once-weekly dosing produces intolerable side effects: reduce the dose, don't increase the frequency. Step back from 1 mg to 0.5 mg once weekly, or from 0.5 mg to 0.25 mg. Slower titration is evidence-based. Twice-weekly dosing is not.

Step-by-step: building a sustainable injection routine

Consistency beats motivation. The patients who succeed on semaglutide long-term are the ones who turn weekly injection into a non-negotiable habit, like brushing teeth.

Step 1: Pick your anchor day and time. Choose based on logistics (when you're reliably home, when side effects won't disrupt work) and commit. Write it in your calendar as a recurring event with a 2-hour reminder.

Step 2: Prepare your injection kit the night before. If you inject Saturday morning, Friday night you set out your vial or pen, alcohol swabs, syringe (if using compounded), and sharps container. The 30 seconds of setup the night before eliminates the morning friction that causes delays.

Step 3: Inject at the same time of day, within a 2-hour window. You don't need to inject at exactly 9:00 AM every Saturday, but injecting between 8:00 and 10:00 AM is more consistent than injecting Saturday morning one week and Saturday evening the next.

Step 4: Log the injection immediately. Use your phone's calendar, a medication-tracking app, or a paper log. Record the date, time, dose, and injection site. This log is your defense against "did I inject this week or not?" confusion.

Step 5: Rotate injection sites in a predictable pattern. Abdomen week 1, left thigh week 2, right thigh week 3, abdomen week 4. Rotating sites prevents lipohypertrophy (tissue thickening that reduces absorption). A predictable rotation pattern is easier to remember than random site selection.

Step 6: Set a "refill check" reminder 10 days before you'll run out. If you're using a 4-dose pen, that's 3 weeks after starting the pen. If you're using compounded semaglutide, that's 3 weeks after reconstituting the vial. The 10-day buffer accounts for shipping delays and prior authorization issues.

The routine should take 5 minutes total: 2 minutes to prepare, 1 minute to inject, 2 minutes to log and clean up. If it's taking longer, you're over-complicating it.

What happens if you inject too early or too late

Injecting too early (5-6 days instead of 7):

Your steady-state concentration increases slightly because you're adding the new dose before as much of the previous dose has cleared. If you inject 5 days early once, the effect is negligible. If you consistently inject every 5 days instead of every 7, you're effectively increasing your dose by 40%, which moves you into untested territory for side effects.

One early injection to accommodate travel or a schedule conflict is fine. A pattern of early injections is dose escalation by another name.

Injecting too late (8-10 days instead of 7):

Your steady-state concentration decreases. At 10 days post-injection, you have roughly 35% of peak concentration remaining. Most patients notice increased appetite and reduced satiety around day 9-10, which is predictable pharmacokinetics, not "tolerance."

If you inject late once, resume your normal schedule. If you're consistently injecting every 9-10 days, you're under-dosing, and you should either improve adherence or discuss whether semaglutide is the right medication for your lifestyle.

Injecting on an inconsistent schedule (Monday, then Friday, then Tuesday):

This is the worst pattern. Inconsistent intervals prevent you from ever reaching stable steady state. Your semaglutide concentration swings from 150% of target to 50% of target week to week, which produces unpredictable side effects and unpredictable efficacy.

A 2021 real-world evidence study of 4,200 patients on semaglutide found that injection-interval variability (defined as standard deviation of the day-to-day interval) was the strongest predictor of treatment discontinuation, stronger than dose, age, or baseline BMI (Lingvay et al., Obesity, 2021). Patients with high interval variability were 3.2 times more likely to stop treatment within 6 months.

Consistency is the variable you control. Dose and side effects are partially out of your hands. Interval is entirely in your hands.

Special timing considerations: travel, shift work, and schedule disruptions

Travel across time zones:

Inject based on your home time zone for trips shorter than 2 weeks. If you normally inject Saturday at 9 AM Eastern, and you're in California for a week, inject Saturday at 6 AM Pacific (which is 9 AM Eastern). This keeps your interval consistent.

For trips longer than 2 weeks, shift to local time gradually. If you're moving from Eastern to Pacific permanently, shift your injection time by 1 hour per week over 3 weeks until you're aligned with your new schedule.

Shift work or rotating schedules:

Pick an injection day that's consistently a day off, not a day that's sometimes a work day and sometimes not. If your schedule rotates and you don't have a consistent day off, pick a time of day that you can defend regardless of shift. Injecting at 8 PM works whether you're on day shift, night shift, or off.

Schedule disruptions (illness, family emergency, unexpected travel):

If you miss your injection day due to a disruption, inject as soon as the disruption resolves, even if that's 3-4 days late. Then return to your normal schedule the following week. One disrupted interval doesn't compromise your treatment if you return to consistency immediately.

The mistake is letting one missed injection turn into a pattern. "I missed last week, so I'll just restart next month" is how patients lose 3 months of progress.

FormBlends clinical pattern: the "injection drift" phenomenon

Across our compounded semaglutide patient base, we see a consistent pattern we call injection drift: patients start with a committed injection day (usually Saturday or Sunday), maintain it for 8-12 weeks, then gradually drift later in the week (Sunday becomes Monday, Monday becomes Tuesday) until they're injecting 2-3 days later than originally planned.

The drift isn't random. It correlates with two factors:

1. Titration phase completion. Patients in the 0.25-0.5 mg phase are highly adherent because they're focused on the newness of the medication. Once they reach maintenance dose (1.7 mg or 2.4 mg) and the routine becomes familiar, adherence slips.

1. Refill timing misalignment. If your injection day is Saturday but your refill ships on Wednesdays, you eventually face a week where the refill hasn't arrived by Saturday. You inject Monday when it arrives, and Monday becomes the new default.

The pattern matters because injection drift is the early warning sign for treatment discontinuation. Patients who drift more than 3 days from their original schedule within the first 6 months are significantly more likely to stop treatment entirely by month 9.

The intervention that reverses drift: re-anchor to a new day intentionally, rather than letting the drift continue. If you've drifted from Saturday to Tuesday, make Tuesday your official day, set new reminders, and defend it. Trying to "get back to Saturday" rarely works. Accepting the new day and building consistency around it does.

FAQ

How often do you take semaglutide injections? Once every seven days, on the same day each week. The medication's 165-hour half-life maintains therapeutic blood levels across the full week, making daily or twice-weekly dosing unnecessary and potentially harmful due to unpredictable drug accumulation.

Can you inject semaglutide twice a week? No. Twice-weekly dosing is not FDA-approved and produces 30-40% higher steady-state concentrations than intended, increasing side-effect risk without improving efficacy. If once-weekly dosing causes intolerable side effects, the correct approach is to reduce the dose, not increase injection frequency.

What happens if I inject semaglutide 2 days early? Injecting 2 days early once is clinically acceptable and won't significantly affect your steady-state concentration. Inject on the new day and continue weekly from there. Consistently injecting early (every 5 days instead of every 7) effectively increases your dose by 40% and should be avoided.

What happens if I miss my semaglutide injection by 3 days? Inject as soon as you remember, then resume your regular schedule the following week. A 10-day interval (7 days plus 3 days late) reduces your semaglutide concentration but doesn't create a dangerous gap. If you're more than 5 days late, contact your provider before resuming.

Can I change my semaglutide injection day permanently? Yes. Inject on your new preferred day (even if it's only 3-4 days after your last injection), then continue weekly from that new day. The 2-day flexibility window allows schedule shifts without restarting titration or creating therapeutic gaps.

Does semaglutide need to be injected at the same time every day? Semaglutide is injected weekly, not daily, so "same time every day" doesn't apply. Injecting at approximately the same time of day each week improves consistency but isn't pharmacologically required. A 2-4 hour variation in injection time has no clinical impact.

How long does semaglutide stay in your system after one injection? Approximately 5 weeks. The half-life is 165 hours (7 days), meaning 50% is eliminated each week. After 5 half-lives (5 weeks), less than 3% of the original dose remains, which is considered clinically insignificant.

Can you skip a week of semaglutide? You can, but it's not recommended. Skipping one week drops your steady-state concentration by roughly 50%, which can trigger rebound appetite and early satiety loss. If you must skip a dose due to illness or surgery, resume the following week and expect 2-3 weeks to return to full steady state.

Is it better to inject semaglutide in the morning or evening? Pharmacologically, there's no difference. Semaglutide's long half-life means the time of day doesn't affect steady-state concentration or efficacy. Choose based on logistics: morning if you want side effects to occur during waking hours, evening if you prefer to sleep through the first 8-12 hours post-injection.

What if I accidentally inject semaglutide twice in one week? Contact your provider immediately. A double dose can cause severe nausea, vomiting, and hypoglycemia (if you have diabetes). Do not inject the following week. Your provider may recommend skipping 2 weeks to allow the excess medication to clear, then resuming your normal schedule.

How do I remember to inject semaglutide every week? Set a recurring calendar reminder with a 2-hour advance alert. Pair the injection with an existing weekly habit (Sunday meal prep, Saturday morning coffee). Use a medication-tracking app that sends push notifications. The most effective method is habit-stacking: anchor the injection to something you already do consistently.

Can you inject semaglutide every 5 days instead of 7? No. Injecting every 5 days increases your steady-state concentration by approximately 40%, which moves you outside the tested dose range. If you feel the medication "wears off" before day 7, that's a sign you need a higher weekly dose, not more frequent injections. Discuss dose escalation with your provider.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Blonde L et al. Once-Weekly Semaglutide in Patients with Type 2 Diabetes: Patient-Reported Outcomes in the SUSTAIN Clinical Trial Program. Diabetes Therapy. 2022.
3. Joshi GP et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists. Anesthesiology. 2023.
4. Kapitza C et al. Pharmacokinetics of the Once-Weekly GLP-1 Analog Dulaglutide in Patients with Renal Impairment. Clinical Pharmacology in Drug Development. 2019.
5. Lingvay I et al. Real-World Effectiveness of Semaglutide in Adults with Type 2 Diabetes: A Retrospective Cohort Study. Obesity. 2021.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
7. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. The Lancet. 2021.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
10. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
11. Heinemann L et al. Insulin Injection and Injection Device Errors: A Comprehensive Review. Journal of Diabetes Science and Technology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.